CareDx (CDNA) Moves 11.5% Higher: Will This Strength Last?

Impact · against what's priced in

CareDx is seeing positive momentum driven by new clinical validation for AlloSure Kidney and strong upcoming earnings projections. LifeMD faces downward pressure as analyst expectations for its near-term earnings have dropped significantly.

CDNA+0.70

No priced-in read yet

In context

The publication of the KOAR study in JASN provides clinical evidence for AlloSure Kidney's role in risk stratification, complementing expected 31.9% revenue growth.

Read from the article alone

• earnings▲4%
• revenue growth▲<1%
• healthcare
• biotech
• CDNA
• LFMD
• clinical study
• molecular diagnostics